Q-omics provides the consensus-scored RPL10P8 profile across patient tissues and cancer cell-line models. RPL10P8 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, RPL10P8 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, RPL10P8 RNA expression shows 8,158 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight CESC, COAD, and UVM as cancer lineages where RPL10P8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL10P8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL10P8 survival associations across molecular data types. RPL10P8 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL10P8 RNA expression–survival associations across cancer types. High RPL10P8 expression shows unfavorable associations in UCEC, LUAD, BRCA and ACC, but favorable associations in CESC and SKCM. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for RPL10P8 RNA expression.
This table summarizes RPL10P8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL10P8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL10P8 shows higher tumor expression in COAD, KIRC, CHOL, KIRP, LUSC and LIHC. The COAD box plot shows higher RPL10P8 RNA expression in tumor versus normal tissue (log2 FC = +1.500, t-test p < 0.001).
This table shows molecular features associated with RPL10P8 in patient tissues and cancer cell lines. In patient samples, RPL10P8 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
